Clinical Trials Logo
  1. Home
  2. ß-thalassemia
  3. NCT05864170

the Safety and Efficacy Evaluation of HGI-001 Injection in Patients With Transfusion-Dependent β-Thalassemia

ß-thalassemia Clinical Trial

Official title:
the Safety and Efficacy Evaluation of HGI-001 Injection in Patients With Transfusion-Dependent β-Thalassemia(Child)

Clinical Trial Summary

This is an open label study to evaluate the safety and efficacy of β-globin Restored Autologous Hematopoietic Stem Cells in ß-Thalassemia Major Patients

Clinical Trial Description

We will recruit ß-thalassaemia major patients and collect their autologous hematopoietic stem cells, which will be modified with the LentiHBBT87Q system to restore β-globin expression. After conditioning, the autologous hematopoietic stem cells with restored β-globin will be reinfused to the patients and followed up for two years to collect data. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05864170
Study type Interventional
Source Shenzhen Hemogen
Contact Haigang Sun
Phone 13823168465
Email sunhaigang@genomics.cn
Status Recruiting
Phase Early Phase 1
Start date May 27, 2022
Completion date August 2025
View Details
See also
  Status Clinical Trial Phase
Completed NCT00560820 - Phase I Study to Examine the Effect of Deferasirox on Renal Hemodynamics in β-thalassemia Patients With Transfusional Iron Overload Phase 1
Recruiting NCT05773729 - Safety and Efficacy of Gene Modified Autologous Hematopoietic Stem Cells to Treat Transfusion-dependent Beta-thalassemia N/A
Completed NCT04054921 - Safety Study for Beta Thalassemia Subjects on PTG-300 Phase 2
Not yet recruiting NCT06440603 - EKLF Gene Expression in β-thalassemia
Recruiting NCT06465550 - A Phase 1 Study of the Safety and Efficacy of Gene Modified Autologous Hematopoietic Stem Cell in β-thalassemia Major Phase 1
Completed NCT03802201 - Study of PTG-300 in Non-Transfusion Dependent and Transfusion-Dependent Beta-Thalassemia Subjects With Chronic Anemia Phase 2
Recruiting NCT05745532 - Safety and Efficacy Evaluation of β-globin Restored Autologous Hematopoietic Stem Cells in β-thalassemia Major Patients Early Phase 1
Not yet recruiting NCT03358498 - Quality of Life and Treatment Satisfaction in β-Thalassemia Patients Receiving Deferasirox N/A
Recruiting NCT05494333 - Correlation Between Pulmonary Functions and Physical Fitness in Children With β-thalassemia